Table 1 Baseline characteristics of the incident NVAF cohort

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

Cohort size

135,241

64,786 (47.90)

70,455 (52.10)

34,659 (25.63)

51,794 (38.30)

48,788 (36.07)

Age, mean (SD)

75.09 (11.41)

73.29 (11.30)

76.73 (11.26)

72.54 (14.65)

75.95 (8.85)

75.98 (10.92)

18-49

4,526 (3.35)

2,643 (4.08)

1,883 (2.67)

2,918 (8.42)

525 (1.01)

1,083 (2.22)

50-59

6,770 (5.01)

3,948 (6.09)

2,822 (4.01)

2,558 (7.38)

1,697 (3.28)

2,515 (5.15)

60-69

22,730 (16.81)

12,736 (19.66)

9,994 (14.18)

6,027 (17.39)

8,408 (16.23)

8,295 (17.00)

70-79

51,018 (37.72)

26,376 (40.71)

24,642 (34.98)

10,977 (31.67)

22,533 (43.51)

17,508 (35.89)

80-89

40,769 (30.15)

16,403 (25.32)

24,366 (34.58)

9,369 (27.03)

16,503 (31.86)

14,897 (30.53)

≥90

9,428 (6.97)

2,680 (4.14)

6,748 (9.58)

2,810 (8.11)

2,128 (4.11)

4,490 (9.20)

Hypertension

83,393 (61.66)

36,683 (56.62)

46,710 (66.30)

17,682 (51.02)

33,651 (64.97)

32,060 (65.71)

Myocardial infarction

27,909 (20.64)

16,186 (24.98)

11,723 (16.64)

3,475 (10.03)

10,081 (19.46)

14,353 (29.42)

Congestive heart failure

27,673 (20.46)

14,025 (21.65)

13,648 (19.37)

5,035 (14.53)

11,325 (21.87)

11,313 (23.19)

Prior stroke or TIA

11,654 (8.62)

5,644 (8.71)

6,010 (8.53)

1,726 (4.98)

5,088 (9.82)

4,840 (9.92)

Prior hemorrhage

21,080 (15.59)

11,160 (17.23)

9,920 (14.08)

6,452 (18.62)

6,437 (12.39)

8,191 (16.79)

Diabetes

34,337 (25.39)

17,893 (27.62)

16,444 (23.34)

6,318 (18.23)

13,688 (26.43)

14,331 (29.37)

Hyperlipidemia

57,433 (42.47)

30,360 (46.86)

27,073 (38.43)

8,165 (23.56)

23,688 (45.74)

25,580 (52.43)

Peripheral vascular disease

16,397 (12.12)

9,857 (15.21)

6,540 (9.28)

2,667 (7.69)

5,900 (11.39)

7,830 (16.05)

Chronic renal failure

14,467 (10.70)

8,228 (12.70)

6,239 (8.86)

3,124 (9.01)

4,960 (9.58)

6,383 (13.08)

Cancer

26,479 (19.58)

15,363 (23.71)

11,116 (15.78)

8,308 (23.97)

8,538 (16.48)

9,633 (19.74)

Charlson index, median (IQR)

1 (0-3)

1 (0-3)

1 (0-2)

1 (0-3)

1 (0-2)

1 (0-3)

0

50,090 (37.04)

21,300 (32.88)

28,790 (40.86)

14,295 (41.24)

20,308 (39.21)

15,487 (31.74)

1-2

49,213 (36.39)

23,036 (35.56)

26,177 (37.15)

11,517 (33.23)

19,606 (37.85)

18,090 (37.08)

≥3

35,938 (26.57)

20,450 (31.57)

15,488 (21.98)

8,847 (25.53)

11,880 (22.94)

15,211 (31.18)

CHADS₂, median (IQR)

2 (1-3)

2 (1-2)

2 (1-3)

1 (1-2)

2 (1-3)

2 (1-3)

0

19,052 (14.09)

10,719 (16.55)

8,333 (11.83)

8,280 (23.89)

5,466 (10.55)

5,306 (10.88)

1

37,744 (27.91)

19,085 (29.46)

18,659 (26.48)

10,741 (30.99)

14,355 (27.72)

12,648 (25.92)

≥2

78,445 (58.00)

34,982 (54.00)

43,463 (61.69)

15,638 (45.12)

31,973 (61.73)

30,834 (63.20)

CHA₂DS₂-VASc, median (IQR)

3 (2-5)

3 (2-4)

4 (3-5)

3 (2-4)

4 (3-5)

4 (3-5)

0

4,209 (3.11)

4,209 (6.50)

0 (0.0)

2,212 (6.38)

875 (1.69)

1,122 (2.30)

1

11,530 (8.53)

7,962 (12.29)

3,568 (5.06)

4,973 (14.35)

3,380 (6.53)

3,177 (6.51)

≥2

119,502 (88.36)

52,615 (81.21)

66,887 (94.94)

27,474 (79.27)

47,539 (91.78)

44,489 (91.19)

HAS-BLED, median (IQR)

2 (1-3)

2 (1-3)

2 (1-3)

1 (1-2)

2 (1-3)

2 (2-3)

≤2

96,763 (71.55)

45,097 (69.61)

51,666 (73.33)

29,400 (84.83)

37,215 (71.85)

30,148 (61.79)

≥3

38,478 (28.45)

19,689 (30.39)

18,789 (26.67)

5,259 (15.17)

14,579 (28.15)

18,640 (38.21)

Antihypertensive drugs**

99,313 (73.43)

45,477 (70.20)

53.836 (76.41)

19,384 (55.93)

40,750 (78.68)

39,179 (80.30)

NSAIDs

49,164 (36.35)

21,617 (33.37)

27,547 (39.10)

12,496 (36.05)

19,003 (36.69)

17,665 (36.21)

Statins

52,132 (38.55)

27,934 (43.12)

24,198 (34.35)

6,873 (19.83)

21,703 (41.90)

23,556 (48.28)